## MEDP: Medpace Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -9.5% below STRENGTH zone (3.0-6.0%); PEG 3.60 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($506.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Medpace Holdings, Inc. (MEDP): A Bull Case Theory**
- Source: Finviz | 20251204T085500 | Bullish | Relevance: 100%
- This article summarizes a bullish thesis on Medpace Holdings, Inc. (MEDP), highlighting its strong operational execution, strategic capital allocation through share repurchases, and fully integrated clinical research model. Medpace's competitive edge in risk mitigation, rather than price, and ongoing investments in AI-driven solutions are driving market share gains and presenting it as a unique investment opportunity. The company continues to show strong revenue and EBITDA growth, with projections for 2025 reflecting profitable and sustainable expansion.

**2. Quantbot Technologies LP Acquires 31,636 Shares of Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251204T043337 | Somewhat-Bullish | Relevance: 100%
- Quantbot Technologies LP significantly increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1,246.0% in Q2, acquiring 31,636 shares to hold a total of 34,175 shares valued at approximately $10.7 million. Medpace reported robust Q3 earnings, surpassing expectations with $3.86 EPS on $659.9 million revenue and provided strong FY2025 guidance. Despite insider selling activity and mixed analyst ratings, the company trades near $588 with a market cap of $16.56 billion.

**3. Medpace Holdings, Inc. (MEDP): A Bull Case Theory**
- Source: Insider Monkey | 20251204T085500 | Bullish | Relevance: 99%
- This article summarizes a bullish thesis on Medpace Holdings, Inc. (MEDP), highlighting its strong operational execution, integrated clinical research model, and strategic capital allocation, including aggressive share buybacks. The company's competitive edge in risk mitigation and execution certainty, along with investments in AI, are driving market share gains and profitable growth. Despite not being a top hedge fund pick, MEDP offers a unique investment opportunity with significant upside.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | BMO Capital | $600 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | BMO Capital | init | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.82M) |
| Sells | 28 ($217.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 8.4% (-4.4%)
- Vanguard Group Inc: 8.1% (-4.5%)
- AQR Capital Manageme: 3.6% (+65.1%)
- Wasatch Advisors LP: 3.3% (-2.1%)
- State Street Corpora: 2.4% (-4.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-6.2% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $217M sold (28 transactions in 90 days).
3. Valuation stretched: PEG 3.6x requires aggressive growth execution.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.60 signals overvaluation risk, limited margin of safety. Forward P/E 33.0x stretched relative to 9% growth. Quality metrics strong (ROE 74%, ROA 16%, margin 18%). Insider selling cluster ($217.3M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.0B |
| Beta | 1.43 |
| 52W Range | $250.05 - $626.25 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.60 |
| Forward P/E | 33.0 |
| Current P/E | 36.0 |
| YoY Growth | 9.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -3.3% to -9.5% (-6.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 12.5pp (needs >3.0% for momentum thesis). Underperforming sector by 8.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.33x) but short-term weakness (below SMA20). MACD histogram bearish (-7.05), momentum weakening. OFD pattern: -MLH (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -9.52% (CS: 1) | Weak |
| RSI_14 | 34.7 | Neutral |
| MACD Histogram | -7.05 | Bearish |
| vs SMA20 | 0.921x | Below |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 1.330x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $544.77
- **Stop Loss:** $506.09 (7.1% risk)
- **Target:** $583.45 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 12
- **Position Value:** $6,537.24
- **Portfolio %:** 6.54%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-09 (Est: $4.21)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.57 | $3.86 | +8.1% |
| 2025Q2 | $3.00 | $3.10 | +3.5% |
| 2025Q1 | $3.07 | $3.67 | +19.6% |
| 2024Q4 | $3.12 | $3.68 | +18.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*